PDF
File
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Vård & Omsorg |
Brain+ has been selected to Biogen's and EIT Health's exclusive Neurotech-prize program. This will give additional momentum to the preparations for launch of Brain+'s first dementia product on the German market in 2023. The German market is a global `reference' market for Digital Therapeutics (DTx) products and succeeding here creates a strong base for global expansion.
The program will give Brain+ direct access to world-class mentors and experts on the German market and provide valuable support to the development of an effective business model and go-to-market strategy for the company's products
The selection by Biogen is the second important stamp of approval for Brain+'s DTx approach from a leading player on the Alzheimer's market
Stamp of approval: The purpose of the Neurotech-prize program is to identify, select and support promising technological solutions to the growing challenge of Alzheimer's disease and to help accelerate their successful commercialization, focusing particularly on the Germany market. Brain+ has been selected alongside 8 other technology companies working with Alzheimer's and is the only company in the group focusing on dementia treatment.
Intensive mentorship to find market fit: Over a period of 10 weeks, Brain+ will undergo an intense mentoring and validation process facilitated by EIT Health and Biogen experts. This will help shape the business model and go-to-market strategy of Brain+ to have the best possible fit with the German market. Following this work, Brain+ will pitch to an independent panel of experts, consisting of leading neurologists, patient representatives and payors who will award €100,000 and €50,000 prizes to the two best solutions among the 9 Neurotech-prize candidates.
World-class mentors: Success in the German market, irrespective of industry and product, is often all about local recognition, integration, and representation. With the program, Brain+ gains access to Biogen's own experts, for example Frauke Schapmann, Head of Alzheimer Business Unit, Biogen Germany and Christiane Sommer, Medical Lead for neurodegenerative diseases, Biogen Germany, as mentors. In addition, the program has gathered leading European experts on commercialization of digital medtech products from the best-in-class medtech start-ups and industry advisors. This includes, for example, the co-founder, Jonas Duss, of the massively successful German digital therapeutics company, Kaia Health, which has been very successful in musculoskeletal (MSK) disorders in Germany and the US, and Alexis Génin, Head of Research and Technology Development, Institut du Cerveau - Paris Brain Institute.
Kim Baden-Kristensen, Co-founder & CEO, Brain+: "The combined experience of these deeply experienced mentors is a gold mine of guidance of how to bring our product effectively forward for commercial success on our first large target market, Germany. We are both proud and humble to be associated with and allowed to learn from these extremely insightful mentors and pioneers in the digital health space and experts in Alzheimer's life science, pharma and neuroscience."
Second global pharma partner: The Neurotech-prize program is a perfect fit with the Brain+ objective of launching in the German market and is a strong and complementary match with the Rox Health (Roche) partnership announced on December 15, 2021 (see company announcement #4) which is designed to assist with the national German regulatory and reimbursement processes. The selection of Brain+ by Biogen to the program is yet another validation and recognition of the potential of Brain+, and its dementia treatment product, Cognitive Stimulation Therapy. For Biogen, the Neurotech-prize program is an opportunity to gain insights into the Brain+ technologies and products.
To learn more, see this short video interview with Brain+ CEO and Chief Commercial Officer, here. https://vimeo.com/687932004
About Biogen, EIT Health and the Neurotech-prize program
Biogen is a leading pharmaceutical player within Alzheimer's disease, who has partnered with EIT Health, Europe's largest Health knowledge and innovation community, to create the Neurotech-prize program, to identify, select and support promising technological solutions to the growing challenge of Alzheimer's disease and to help accelerate their successful commercialization, focusing particularly on the Germany market.
Read more here: https://nordiclifescience.org/eit-health-and-biogen-launch-neurotech-prize/
About Biogen: https://www.biogen.com/en_us/alzheimers-disease.html
About EIT Health: https://eithealth.eu/who-we-are/
EIT Health CEO about Neurotech-prize program: "Alzheimer's, alongside cancer, is our next big challenge following COVID-19. The pandemic has shown us clearly what can be achieved when science is put in the driving seat, and collaboration and focus are the words of the day. We must now use those lessons and the momentum to solve the devastating diseases that have been affecting us for a long time but will affect us much more acutely in the near future. Our experience tells us that while there are many great healthcare ideas waiting to be unlocked, the real difficulty is finding the right people and environments to deliver them to the market quickly and effectively. Direct collaboration between EIT Health and Biogen will give us all of the ingredients to foster, grow and test ideas, and rapidly commercialise those that can have impact," said Jan-Philipp Beck, CEO of EIT Health.
About BRAIN+ [BRAINP]
PROBLEM: Dementia is a terrible condition, crippling a person's independence and putting a heavy burden also on the family. With an aging population, dementia is threatening to overwhelm the health care systems of the world. New treatments and therapies are greatly needed.
VISION: Making effective dementia treatments available to everyone, as digital medicine.
MISSION: To restore patients' independence and quality of life by treating and detecting cognitive decline in Alzheimer's disease and dementia.
SOLUTION: Digitizing best-in-class non-drug dementia therapies and enhancing them with cutting edge digital technologies, together with the world's leading experts, making them available on computers and smart phones in people's homes or at the clinic. A therapy here, simply means a person having to actively do something, interacting with a software program or another person, which is stimulating to the brain, or which results in changes in behavior that brings measurable health benefits. Such therapies can be used on their own or be combined with traditional drug treatments.
OUR DNA: We operate like a digital biotech company; our technologies and products are being rigorously tested, scientifically and clinically validated, regulated as medical products, and reimbursed and paid for by the state or health insurances.
POTENTIAL: The global costs of dementia will be $2 trillion in 2030 (or equal to 2/3rds of the entire health care spend of the USA), the estimated market potential which our digital products could address will be $24 billion and growing rapidly, and our target in 2030 is revenue in the hundreds of millions $ based on licensing deals with strategic commercial partners, and we aim to close a first large multi-million $-deal in 2025.
TEAM & TECH: We have built our knowledge base, know-how and network of global expert collaborators, over 10 years, and our technology portfolio is the results of R&D investments of over €10 million, which puts us in a unique position to become a global market leader in digital therapeutic solutions for dementia and Alzheimer's. We have a team with the deep and necessary expertise to succeed, including our Director of Science & Innovation from Coloplast, our CTO from Lundbeck, our Chief Commercial from Novartis, and our CFO from GN Hearing.